Results 21 to 30 of about 38,467 (231)
Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy [PDF]
BMC PsychiatryBackground Malignant hyperthermia is a potentially lethal condition triggered by specific anesthetic drugs, especially a depolarizing muscle relaxant of succinylcholine (Suxamethonium).
Nakano M +8 more
europepmc +2 more sources
Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil [PDF]
Revista Brasileira de Anestesiologia, 2019 Background and objectives: Malignant hyperthermia is an autosomal dominant hypermetabolic pharmacogenetic syndrome, with a mortality rate of 10%–20%, which is triggered by the use of halogenated inhaled anesthetics or muscle relaxant succinylcholine. The
Helga Cristina Almeida da Silva +7 more
doaj +5 more sources
Malignant Hyperthermia in PICU—From Diagnosis to Treatment in the Light of Up-to-Date Knowledge
Children, 2022 Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile anesthetics and succinylcholine. Rarely, MH can occur after non-pharmacological triggers too. MH was detected more often in children and young adults, which
Martina Klincová +4 more
doaj +1 more source
Malignant hyperthermia: a case report with a literature review [PDF]
Archives of Aesthetic Plastic Surgery, 2022 Malignant hyperthermia is an extremely rare, potentially lethal disorder that occurs in susceptible patients who are exposed to triggering agents such as volatile anesthetic gases or depolarizing muscle relaxants. The clinical manifestations of malignant
Ji Hoon Kim +4 more
doaj +1 more source
European Journal of Anaesthesiology, 2001 Malignant hyperthermia is an autosomal-dominant inherited disorder of the skeletal muscle cell characterized by a hypermetabolic response to all commonly used inhalational anaesthetics and depolarizing muscle relaxants. The clinical syndrome includes muscle rigidity, hypercapnia, tachycardia and myoglobinuria as result of increased carbon dioxide ...
J K, Kozack, D L, MacIntyre
openaire +5 more sources
Impact of a digital manual for guidance on malignant hyperthermia: patient education
Orphanet Journal of Rare Diseases, 2022 Background Malignant hyperthermia (MH) is a rare, hereditary disease with a hypermetabolic response to volatile anesthetics/succinylcholine. Susceptible patients face difficulties due to a lack of knowledge about MH.
Gislene Rodrigues +4 more
doaj +1 more source
Postgraduate Medical Journal, 1998 SummaryMalignant hyperthermia is a rare autosomal dominant trait that predisposes affected individuals to great danger when exposed to certain anaesthetic triggering agents (such as potent volatile anaesthetics and succinylcholine). A sudden hypermetabolic reaction in skeletal muscle leading to hyperthermia and massive rhabdomyolysis can occur.
R, Ben Abraham +3 more
openaire +4 more sources
Frontiers in Physiology, 2021 Aging causes skeletal muscles to become atrophied, weak, and easily fatigued. Here, we have tested the hypothesis that normal aging in skeletal muscle cells is associated with Ca2+ intracellular dyshomeostasis and oxidative stress.
Alfredo Mijares +2 more
doaj +1 more source
ASA Refresher Courses in Anesthesiology, 1980 In MH, skeletal muscle acutely and unexpectedly increases its oxygen consumption and lactate production, resulting in greater heat production, respiratory and metabolic acidosis, muscle ridigity, sympathetic stimulation, and increased cellular permeability.
Gerald A. Gronert, Bryan E. Marshall
+7 more sources
eLife, 2020 Most glucose is processed in muscle, for energy or glycogen stores. Malignant Hyperthermia Susceptibility (MHS) exemplifies muscle conditions that increase [Ca2+]cytosol. 42% of MHS patients have hyperglycemia.
Eshwar R Tammineni +7 more
doaj +1 more source